1,4-dioxa-8-azaspiro[4.5]decan-8-yl-(3-methyl-2-benzofuranyl)methanone is a complex organic molecule with a specific structure. It's important to understand the structural elements to understand its potential importance in research:
* **1,4-dioxa-8-azaspiro[4.5]decan-8-yl:** This part refers to a spirocyclic ring system. Spiro indicates that two rings share a single atom (in this case, the carbon atom at position 8). The 'dioxa' portion indicates two oxygen atoms within the ring system, and the 'aza' indicates a nitrogen atom. The numbers refer to the positions of these atoms within the ring system.
* **(3-methyl-2-benzofuranyl)methanone:** This refers to a benzofuran derivative (a heterocyclic system containing a benzene ring fused to a furan ring) with a methyl group at position 3 and a ketone (methanone) group attached to the furan ring.
**Importance in Research:**
The specific importance of this molecule would depend on the research area it's being investigated in. However, based on its structure, it could be relevant in several fields:
* **Medicinal Chemistry:** The combination of spirocyclic, heterocyclic, and ketone functionalities makes this molecule a potential candidate for drug discovery. It could exhibit pharmacological activity targeting specific receptors or enzymes.
* **Materials Science:** The rigidity and specific functional groups within the molecule could make it useful as a building block for new materials with desired properties like conductivity, optical properties, or mechanical strength.
* **Organic Synthesis:** This complex molecule could serve as a challenging target molecule in the development of new synthetic methodologies or the exploration of novel reactions.
**To understand the specific importance of this molecule in research, you need further context.** What research area is it related to? What are its properties? What are its potential applications?
**Here's how to find out more:**
* **Search online databases:** Use databases like PubChem, SciFinder, or Reaxys to find information about the molecule, including its properties, synthesis, and research publications.
* **Look up the specific research:** If you know the research area or project where this molecule is being investigated, search for relevant publications or presentations.
By gathering more information, you can determine the significance of 1,4-dioxa-8-azaspiro[4.5]decan-8-yl-(3-methyl-2-benzofuranyl)methanone in the context of specific research goals.
ID Source | ID |
---|---|
PubMed CID | 1244286 |
CHEMBL ID | 1452971 |
CHEBI ID | 120953 |
Synonym |
---|
REGID_FOR_CID_1244286 |
smr000080249 |
8-[(3-methyl-1-benzofuran-2-yl)carbonyl]-1,4-dioxa-8-azaspiro[4.5]decane |
MLS000065614 |
1,4-dioxa-8-azaspiro[4.5]dec-8-yl(3-methyl-1-benzofuran-2-yl)methanone |
STK462193 |
OPREA1_713566 |
CHEBI:120953 |
AKOS003289847 |
1,4-dioxa-8-azaspiro[4.5]decan-8-yl-(3-methyl-1-benzofuran-2-yl)methanone |
HMS2431I06 |
CHEMBL1452971 |
1,4-dioxa-8-azaspiro[4.5]decan-8-yl-(3-methyl-2-benzofuranyl)methanone |
Q27209154 |
sr-01000291194 |
SR-01000291194-1 |
Class | Description |
---|---|
azaspiro compound | An azaspiro compound is a spiro compound in which at least one of the cyclic components is a nitrogen heterocyle. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 28.1838 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 3 (60.00) | 24.3611 |
2020's | 1 (20.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.56) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |